Omicron infection is a poor booster of COVID-19 immunity

A common assumption of the COVID-19 pandemic has been that through being infected with the virus you gain a natural immune boost, leaving you better able to recognise the variant you’ve encountered and fend off infection in the future.

However, the latest analysis finds that Omicron provides a poor natural boost of COVID-19 immunity against re-infection with Omicron itself even in people who are triple-vaccinated.

In those who were triple vaccinated and had no prior SARS-CoV-2 infection, Omicron infection provided an immune boost against previous variants (Alpha, Beta, Gamma, Delta and the original ancestral strain), but less so against Omicron itself. Those infected during the first wave of the pandemic and then again later with Omicron lacked any boosting.

The team conducting the study was made up of researchers from Imperial, Barts Health NHS Trust, UK Health Security Agency, Royal Free Hospital NHS Trust and University College London. They say that their findings may help to explain why ‘breakthrough’ and repeat infections have been a common feature of the Omicron wave of the pandemic. However, the team stress that vaccination continues to provide protection against severe disease and death.

It has been argued that even if antibody recognition of Omicron is poor, T cell immunity may be ready to fill the gap to achieve effective protection. However, the study showed poorer recognition of Omicron spike antigen by T cells in those who had been Omicron infected.

Previous work by the team found that patterns of immunity against SARS-CoV-2 are ‘imprinted’ on the immune system by infection history. Your imprint is determined by the number of vaccine doses you have received and the variant that you come in to contact with, resulting in different immunity across different individuals in the population.

In the latest study, they looked at why there are so many Omicron breakthrough infections, even among people who have been triple vaccinated; how this is affected by previous infection history; and whether Omicron infection at least offers a ‘natural booster’ of COVID-19 immunity.

The team analysed blood samples from UK healthcare workers who received three doses of mRNA vaccine, and who had different SARS-CoV-2 infection histories, to investigate antibody, T and B cell immunity against Omicron.

They found that people with no prior SARS-CoV-2 infection who then had Omicron showed enhanced cross-reactive immunity to previous variants – with enhanced B and T cell immunity against Alpha, Beta, Gamma and Delta – but they showed a reduced boosting against the Omicron spike protein itself.

Healthcare workers with prior Alpha infection showed a less sustained antibody response against Omicron. People infected during the first wave of the pandemic and then again with Omicron lacked any immune boosting, in an effect the researchers termed ‘hybrid immune damping’.

According to the researchers, the impact of immune imprinting means that after infection with Omicron people who had previously been infected during the first wave are not immune boosted against a subsequent infection with the variant, and potentially its subvariants BA.4 and BA.5. They highlight that while vaccination provides protection against severe disease, the impact of infection and re-infection on long term health, including long COVID, is not known. The current study only focused on triple mRNA vaccinated individuals.

Dr Joseph Gibbons, from Queen Mary University of London and study author, added:

“The link between a person’s infection history and their response to the vaccine is now clear. Previous infection with different variants impacts both the potency and durability of your immune responses. The effectiveness of current vaccination strategies will depend not only on which variants become dominant in the future, but also on how previous waves of infection have impacted our immunity.”

“We show that ‘hybrid immune damping’ can occur. For example, infection with the ancestral virus strain impairs the boosting effect of a subsequent Omicron infection. The broad diversity of infection history in our population means that further exposure to the current vaccine has different implications for different people.” 

Dr Catherine Reynolds, from Imperial’s Department of Infectious Disease, further commented:

"Now, with such diverse patterns of SARS-CoV2 infection and vaccination across different global populations, it is more important than ever to understand the immune impacts of these patterns and how they might shape immunity to future variants. Our study shows that an individual’s vaccination and infection history can have a huge bearing on their immune response to variants, including to Omicron."

The study was carried out in collaboration with researchers at Imperial, Barts Health NHS Trust, UK Health Security Agency, Royal Free Hospital NHS Trust and University College London using detailed, longitudinal follow-up of the UK COVIDsortium healthcare worker cohort of 731 individuals, who have been followed since March 2020.

This work was specifically supported by the DuRaCoV award (UKRI, MR/W020610/1). The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Kenneth C Griffin, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University of London.

‘Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure’ by Catherine J Reynolds, et al. is published in Science. DOI: 10.1126/science.abq1841

https://www.science.org/doi/10.1126/science.abq1841